Technology
Health
Biotechnology

Mesoblast

$5.22
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.05 (0.99%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Mesoblast and other stocks, options, ETFs, and crypto commission-free!

About

Mesoblast Limited American Depositary Shares, also called Mesoblast, is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. Read More The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Employees
81
Headquarters
Melbourne, Victoria (VIC)
Founded
2004
Market Cap
510.57M
Price-Earnings Ratio
Dividend Yield
Average Volume
63.41K
High Today
$5.53
Low Today
$5.15
Open Price
$5.37
Volume
60.32K
52 Week High
$8.78
52 Week Low
$3.35

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical

News

Markets InsiderMar 13

Mesoblast Features at Upcoming U.S. Investor Conferences

NEW YORK and MELBOURNE, Australia, March 13, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced it will be featured at two investor conferences in March: Oppenheimer 29th Annual Healthcare Conference in New York on Wednesday, March 20, 2019 at 1:00 p.m. ET. The Alliance for Regenerative Medicine’s Seventh Annual Cell & Gene Therapy Investor Day in New York on Thursday, March 21, 2019 at 4:15 p.m. ET. About Mesoblast Mesoblast Limited (ASX: MSB; Nasdaq: MESO) is a world...

470
Simply Wall StMar 10

Before You Buy Mesoblast Limited (ASX:MSB), Consider Its Volatility

If you’re interested in Mesoblast Limited (ASX:MSB), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio.

890
MarketBeatMar 10

Stock Price, News, & Analysis for Mesoblast

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing M...

0

Earnings

-$0.26
-$0.18
-$0.10
-$0.02
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected May 29, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.